FDA Requires Vision Damage Warnings on Wegovy, Mounjaro, and other GLP-1 Drugs

The U.S. Food and Drug Administration (FDA) has mandated new 'vision damage risk warnings' for the labels of GLP-1 class obesity and diabetes medications, including Wegovy, Ozempic, Mounjaro, and Zepbound. This regulatory action follows a review of clinical trials, animal experiments, and patient data, which indicated a potential increased risk of optic nerve damage, specifically non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to permanent vision loss. An FDA analysis of 126 clinical trials found 6.4 NAION cases per 100,000 person-years in GLP-1 users compared to 3.8 cases in control groups.